{"id":"W1907039258","doi":"10.1111/apt.13408","title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","year":2015,"lang":"en","type":"article","venue":"Alimentary Pharmacology & Therapeutics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":173,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"UCB Pharma; Takeda Oncology; Tillotts Pharma; Genentech; Biogen; Celgene; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Wyeth Pharmaceuticals; Pfizer; ActoGeniX; Bristol-Myers Squibb","keywords":"Medicine; Ulcerative colitis; Mesalazine; Placebo; Internal medicine; Interim analysis; Clinical trial; Inflammatory bowel disease; Clinical endpoint; Interim; Endoscopy; Colonoscopy; Gastroenterology; Disease; Surgery; Pathology; Alternative medicine; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003366178,0.0001887304,0.0004262932,0.00004677496,0.00005252459,0.000005481876,0.0002267158,0.0001007223,0.00002338641],"category_scores_gemma":[0.00002084786,0.0001454099,0.0002161564,0.00005322489,0.0002378515,0.000008392299,0.0001357242,0.0001247797,4.907554e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007735049,"about_ca_system_score_gemma":0.0008614263,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008595455,"about_ca_topic_score_gemma":0.00006886807,"domain_scores_codex":[0.9966285,0.001348963,0.001305423,0.000285369,0.0002102799,0.0002214937],"domain_scores_gemma":[0.9983591,0.0002910272,0.0007075215,0.0002659391,0.0002302778,0.0001461223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.03434663,0.003771054,0.4238443,0.0001269279,0.02199529,0.00005860121,0.001375731,0.0005116723,0.4881409,0.00005832424,0.001054318,0.02471631],"study_design_scores_gemma":[0.009397419,0.0008276449,0.7148768,0.00001995432,0.004349746,0.000002147711,0.0006852825,0.001063871,0.2576979,0.00006112822,0.01068066,0.0003375491],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956237,0.000192211,0.001335533,0.0004201776,0.0007938815,0.001473903,0.0001280471,0.000005685857,0.00002685713],"genre_scores_gemma":[0.9962401,0.00007894454,0.00134764,0.001838106,0.00009343221,0.0002859361,0.00008014055,0.00001960007,0.0000161418],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2910325,"threshold_uncertainty_score":0.5929643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2507047214101915,"score_gpt":0.4853118432067941,"score_spread":0.2346071217966026,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}